Genetic Alliance researchers have come up with recommendations for the UK's NHS on how to incorporate whole-genome sequencing into standard cancer care.
Researchers from St. Jude Children's and the German Cancer Research Center used methylation and gene expression analyses to uncover the subtypes.
The Belgian cancer diagnostics firm will provide the lab with access to its OncoDeep DX Plus and Clinical Plus services.
Both studies found that about 40 percent of pediatric cancer patients have mutations with potential clinical significance, either for diagnosis or treatment.
The researchers performed targeted sequencing using Thermo Fisher Scientific's Oncomine Comprehensive Panel and the Ion Torrent PGM or Proton.
The partners will develop an NGS panel for solid and liquid tumors for use in personalized oncology.
Reimbursement from private insurers continues to grow, with United Healthcare recently saying it will cover molecular profiling for stage IV non-small cell lung cancer patients.
Under the terms of the agreement, N-of-One will provide clinical interpretation services for samples sequenced on a 50-gene hot-spot solid tumor panel.
The combined offering will enable customers to assess health outcomes and therapy effectiveness at the patient-anonymous level.
The Broad will partner with Dana-Farber/Harvard Cancer Center and Memorial Sloan Kettering Cancer Center on a large tumor sequencing study.
23andMe is offering early customers re-testing on newer chips for a fee, Wired reports.
He Jiankui is no longer affiliated with Direct Genomics Biotechnology, the single molecule sequencing company he founded, Nikkei Asian Review reports.
Newsweek writes about the hopes for precision medicine in cancer, but also challenges getting it to patients.
In Genome Research this week: genomic architecture of glioblastoma, predictive computational approach to estimate SNP fitness, and more.